Multidrug resistance mechanisms and therapeutic strategies in Candida auris
DOI:
https://doi.org/10.18203/2320-6012.ijrms20252187Keywords:
C. auris, Resistance, Multidrug resistance, Mechanisms therapeuticAbstract
In recent years, Candida auris has emerged as a formidable global health threat due to its multidrug resistance, high transmissibility in healthcare settings, and diagnostic challenges. Unlike most Candida species, C. auris can colonize the skin, persist on surfaces, and resist common antifungal agents including azoles, echinocandins, and polyenes. Its rapid global spread and association with high mortality in immunocompromised patients have drawn intense clinical and scientific attention. This review aims to consolidate current knowledge on the mechanisms underlying antifungal resistance in C. auris, including genetic mutations in target enzymes (e.g., ERG11, FKS1), overexpression of efflux pumps, biofilm formation, and stress response pathways. Additionally, it explores the pathogen’s virulence factors, diagnostic challenges, and environmental resilience. We also provide a critical overview of emerging therapeutic strategies, including novel antifungal agents, combination therapies, and immunotherapeutic interventions. Special emphasis is given to the ongoing clinical trials and pipeline antifungals such as ibrexafungerp, manogepix, and rezafungin. The review concludes with future directions for research, highlighting the need for improved surveillance, molecular diagnostics, and antifungal stewardship to curb the rise of this deadly fungal pathogen.
Metrics
References
Borman AM, Szekely A, Johnson EM. Comparative pathogenicity of UK isolates of Candida auris and other key pathogenic Candida species. mSphere. 2016;1(4):e00189-16. DOI: https://doi.org/10.1128/mSphere.00189-16
Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Calvo B, et al. Simultaneous emergence of multidrug-resistant Candida auris on three continents. Clin Infect Dis. 2017;64(2):134-40. DOI: https://doi.org/10.1093/cid/ciw691
Chowdhary A, Sharma C, Hagen F, Meis JF. Exploring azole antifungal drug resistance in emerging pathogenic yeast Candida auris. Future Microbiol. 2014;9(5):585-600. DOI: https://doi.org/10.2217/fmb.14.27
Centers for Disease Control and Prevention (CDC). Tracking Candida auris. 2023. Available at: https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. Accessed on 10 June 2025.
Chaabane F, Graf A, Jequier L, Coste AT. Multiple molecular mechanisms contribute to antifungal resistance in Candida species. J Fungi. 2019;5(4):87.
Satoh K, Makimura K, Hasumi Y, Yayoi N, Katsuhisa U, Hideyo Y. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41-4. DOI: https://doi.org/10.1111/j.1348-0421.2008.00083.x
Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16(10):e1008921. DOI: https://doi.org/10.1371/journal.ppat.1008921
World Health Organization (WHO). Fungal priority pathogens list to guide research, development and public health action. 2023. Available at: https://www.who.int/publications/i/item/9789240060241. Accessed on 14 June 2025.
Ostrowsky B, Greenko J, Adams E, Quinn M, O'Brien B, Chaturvedi S, et al. Candida auris isolates resistant to three classes of antifungal medications-New York, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(1):6-9. DOI: https://doi.org/10.15585/mmwr.mm6901a2
Rybak JM, Doorley LA, Nishimoto AT, Barker KS, Rogers PD. Mutations in TAC1B: a novel genetic determinant of clinical fluconazole resistance in Candida auris. mBio. 2020;11(3):e00365-20. DOI: https://doi.org/10.1128/mBio.00365-20
Carolus H, Pierson S, Lagrou K, Van Dijck P. Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance. J Fungi. 2020;6(4):321. DOI: https://doi.org/10.3390/jof6040321
Horton MV, Johnson CJ, Kernien JF. Nonaggregative and aggregative Candida auris biofilm heterogeneity: biomass and impedance-based analyses. mBio. 2020;11(5):e01700-20.
Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Meis JF, et al. A multicentre study of antifungal susceptibility patterns among 350 clinical Candida auris isolates. J Antimicrob Chemother. 2018;73(4):891-9. DOI: https://doi.org/10.1093/jac/dkx480
Wall G, Garcia-Rubio R, Aguilar S, Dominguez Á, Pemán J. In vitro activities of manogepix and other antifungal agents against Candida auris isolates from Spain. Antimicrob Agents Chemother. 2020;64(5):e02136-19.
Wiederhold NP. Emerging fungal resistance to echinocandins: clinical relevance and therapeutic implications. Future Microbiol. 2021;16(3):197-208.
Bidaud AL, Chowdhary A, Dannaoui E. Candida auris: an emerging drug-resistant yeast-a mini-review. J Mycol Med. 2022;32(1):101-6.
Pfaller MA, Messer SA, Rhomberg PR, Castanheira M. Activity of a long-acting echinocandin (rezafungin) and comparator agents against clinical isolates of Candida species, including multidrug-resistant isolates. J Antimicrob Chemother. 2020;75(3):767-71.
Thompson GR, Soriano A, Skoutelis A, Cantón E, Ostrosky-Zeichner L, Kontoyiannis DP. Early clinical experience with fosmanogepix (APX001) for invasive fungal infections. Clin Infect Dis. 2021;73(7):1298-306.
Gonçalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL. Epidemiological and molecular aspects of Candida auris: a global threat. Mycoses. 2017;60(9):646-59.
Muñoz JF, Gade L, Chow NA, Loparev VN, Juieng P, Berkow EL, et al. Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun. 2018;9(1):5346. DOI: https://doi.org/10.1038/s41467-018-07779-6
Chow NA, Gade L, Tsay SV, Kaitlin F, Greenko JA, Southwick KL, et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis. 2020;20(12):1372-80.
Kean R, Ramage G. Combined antifungal resistance and biofilm tolerance: the global threat of Candida auris. mSphere. 2019;4(4):e00458-19. DOI: https://doi.org/10.1128/mSphere.00458-19
Abdolrasouli A, Armstrong-James D, Ryan L. The challenge of Candida auris: a review of current diagnostic and management strategies. Mycoses. 2017;60(10):618-28. DOI: https://doi.org/10.1111/myc.12699
Schelenz S, Hagen F, Rhodes JL, Alireza A, Anuradha C, Anne H, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5(1):35. DOI: https://doi.org/10.1186/s13756-016-0132-5
Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R, Quan TP, et al. A Candida auris outbreak and its control in an intensive care setting. N Engl J Med. 2018;379(14):1322-31. DOI: https://doi.org/10.1056/NEJMoa1714373
Arastehfar A, Carvalho A, Houbraken J, et al. Candida auris: epidemiology, diagnostics, and resistance mechanisms. J Clin Microbiol. 2020;58(5):e01588-19.
Ghannoum M, Long L, Larkin E. Evaluation of antifungal activity of SCY-078, rezafungin, and APX001A against Candida auris in vivo. Antimicrob Agents Chemother. 2020;64(9):e01754-19. DOI: https://doi.org/10.1128/AAC.00854-20
Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science. 2012;336(6082):647. DOI: https://doi.org/10.1126/science.1222236
Nami S, Mohammadi R, Vakili M, Khezripour K. Fungal vaccines, mechanisms of action and immunology: A comprehensive review. Biomed Pharmacother. 2019;109:333-44. DOI: https://doi.org/10.1016/j.biopha.2018.10.075
Downloads
Published
How to Cite
Issue
Section
